INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 30 September 2013
|
Total net assets |
£180.0m |
|
NAV per share |
326.5p |
|
Share price |
286.5p |
|
Total value of unquoted investments |
£23.7m |
|
Total number of portfolio companies |
77 |
Top Five Holdings
|
Company Name |
% NAV |
|
Celgene |
8.5 |
|
Gilead |
7.0 |
|
Regeneron |
6.8 |
|
Amgen |
6.5 |
|
Biogen |
5.8 |
|
|
----------- |
|
Total |
34.6 |
|
Trust Characteristics |
% NAV |
|
Profitable |
56 |
|
Becoming Profitable |
13 |
|
Unprofitable |
31 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
United States & Canada |
93 |
|
Europe |
7 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted allocation |
% NAV |
|
Quoted |
87 |
|
Unquoted |
13 |
|
|
----------- |
|
Total |
100 |
|
Subsector |
% NAV |
|
Therapeutics |
82 |
|
Life Sciences Tools, Diagnostics & Services |
9 |
|
Medical Devices |
5 |
|
Specialty Pharma |
4 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
30 OCTOBER 2013